AMRX (Amneal Pharmaceuticals, Inc.) Stock Financials & Earnings

AMRXAmneal Pharmaceuticals, Inc.

Mkt Cap$4B

Revenue (TTM)$3.0B

Net Income (TTM)$72M

EPS (TTM)$0.22

Free Cash Flow (TTM)$237M

Gross Margin36.9%

Op. Margin10.8%

Net Margin2.4%

FCF Margin7.8%

P/S Ratio (TTM)1.4x

P/E Ratio (TTM)58.9x

YoY Rev Growth+8.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$558M	$178M	$34M
Q2 23	$599M	$220M	$80M
Q3 23	$620M	$233M	$76M
Q4 23	$617M	$225M	$14M
Q1 24	$659M	$238M	-$11M
Q2 24	$702M	$250M	$95M
Q3 24	$702M	$270M	$89M
Q4 24	$731M	$263M	$76M
Q1 25	$695M	$256M	$100M
Q2 25	$725M	$286M	$111M
Q3 25	$785M	$274M	-$117K
Q4 25	$814M	$297M	$115M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$40M	—	—	$102M
Q2 23	$39M	—	—	$106M
Q3 23	$42M	—	—	$113M
Q4 23	$47M	$97M	$12M	—
Q1 24	$39M	—	—	$113M
Q2 24	$37M	—	—	$116M
Q3 24	$61M	—	—	$119M
Q4 24	$56M	$94M	$34M	—
Q1 25	$42M	—	—	$118M
Q2 25	$50M	—	—	$124M
Q3 25	$63M	—	—	$138M
Q4 25	$35M	—	—	$146M

Revenue Segments

Quarter	Amneal Specialty Pharma Segment	Av K A R E Segment	Generics Segment
Q1 23	$92M	$122M	$344M
Q2 23	$97M	$128M	$374M
Q3 23	$97M	$132M	$391M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$145M	$3M	$148M
Q2 23	$109M	$3M	$113M
Q3 23	$87M	$5M	$92M
Q4 23	$92M	$2M	$94M
Q1 24	$48M	$0	$48M
Q2 24	$44M	$3M	$47M
Q3 24	$74M	$0	$74M
Q4 24	$111M	$2M	$112M
Q1 25	$59M	$0	$59M
Q2 25	$81M	$0	$81M
Q3 25	$201M	$0	$201M
Q4 25	$311M	$0	$311M

Shares Outstanding

Revenue Per Employee

Revenue / Employee